Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 11, 2011, Pages 1873-1876

  Toldi, Gergely ^a,b   Bíró, Edina ^a   Szalay, Balázs ^a,b   Stenczer, Balázs ^c   Molvarec, Attila ^c   Rigó Jr , János ^c   Vásárhelyi, Barna ^a,b   Beko, Gabriella ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

High sensitivity C reactive protein; IL 6; Preeclampsia; Pregnancy; SuPAR

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; UROKINASE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THIRD TRIMESTER PREGNANCY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HUNGARY; INFLAMMATION; INTERLEUKIN-6; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; ROC CURVE; SOLUBILITY;

EID: 80755130081     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.656     Document Type: Article

References (15)

1. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF 3rd, Petraglia F. Inflammation and pregnancy. Reprod Sci 2009;16: 206-15.
2. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506. (Pubitemid 29093892)
3. Saito S, Umekage H, Sakamoto Y, Sakai M, Tanebe K, Sasaki Y, et al. Increased T-helper-1-type immunity and decreased T-helper- 2-type immunity in patients with preeclampsia. Am J Reprod Immunol 1999;41:297-306. (Pubitemid 29245760)
4. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009;27:157-72.
5. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000;96: 4091-5.
6. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004;36:14-9. (Pubitemid 38219765)
7. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng Adjei G, Pedersen BK, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191:1331-41.
8. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 2001;8:1196-203. (Pubitemid 33035755)
9. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9. (Pubitemid 28217457)
10. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV. (Pubitemid 32672922)
11. Toldi G, Stenczer B, Molvarec A, Takats Z, Beko G, Rigo J Jr, et al. Hepcidin concentrations and iron homeostasis in preeclampsia. Clin Chem Lab Med 2010;48:1423-6.
12. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010;268:296-308.
13. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999;79:717-22. (Pubitemid 29283425)
14. Riisbro R, Christensen IJ, Høgdall C, Brünner N, Høgdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001; 16:233-9. (Pubitemid 34168381)
15. Ostrowski SR, Shulman CE, Peshu N, Staalsøe T, Høyer- Hansen G, Pedersen BK, et al. Elevated plasma urokinase receptor predicts low birth weight in maternal malaria. Parasite Immunol 2007;29:37-46. (Pubitemid 44934847)